Chimeric antigen receptor (CAR) T-cell therapy is a cellular immunotherapy that redirects the killing activity of T cells to fight tumor cells. CD19 CAR T-cell therapies have demonstrated high rates of complete response in clinical trials in patients with relapsed or refractory B-cell malignancies and have been associated with on-target side effects.OBJECTIVES:
This article describes educational opportunities for patients and families during the CAR T-cell therapy procedure, highlighting specific points where education by nurses is critical for safety and protocol adherence.METHODS:
Current literature on CAR T-cell therapy was reviewed and supported by the authors' professional experiences.FINDINGS:
CAR T-cell therapy is a novel treatment, and repetition of information and building the knowledge base of patients and families is important. The role of nurses in educating patients about the side effects of CAR T-cell therapy is critical for the safety and psychological well-being of patients.